To assess efficacy of the novel, selective poly-(ADP-ribose)-polymerase-1 (PARP) inhibitor AZD2281 against newly established BRCA2-deficient mouse mammary tumor cell lines and to determine potential synergy between AZD2281 and cisplatin.
Introduction
Mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 are responsible for the majority of hereditary breast cancers 1 . Tumors in patients with heterozygous BRCA1 or BRCA2 germ-line mutations typically show somatic loss of heterozygosity (LOH) at the BRCA1 or BRCA2 locus, respectively, resulting in loss of the wild-type allele 2, 3 . Functionally, involvement of BRCA2 in the repair of DNA damage, especially DSBs has been firmly established by several groups [4] [5] [6] . The primary role of BRCA2 in this process appears to be the regulation of damage-induced RAD51 protein filaments that are required for DSB repair by homologous recombination (HR) 7 .
In the absence of BRCA2, repair of DSBs by error-prone mechanisms 8 and chromosomal instability due to improper centrosome maintenance 9 result in genomic instability 10 , which renders cells susceptible to acquiring additional cancer initiating genetic lesions. The absence of error-free DSB repair mechanisms may prove to be the Achilles heel of BRCA2-deficient tumors, as increased sensitivity to γ-irradiation or DNA damaging agents is observed in cells with dysfunctional BRCA2 4, [11] [12] [13] . Clinical trials exploiting the sensitivity of BRCA-mutated breast cancers to platinum-based DNA damaging drugs have been started recently 14, 15 .
Since platinum based monotherapy is associated with toxicity 16 , alternative strategies to stress the DSB repair pathway are urgently needed. An attractive strategy, which has recently gained momentum, is based on inhibition of poly-(ADP-ribose)-polymerase 1 (PARP-1), which binds to DNA strand breaks and helps regulate base excision repair (BER). Upon binding, both the protein itself and surrounding histones are poly ADP-ribosylated, which may help in attracting repair factors, such as the single-strand break (SSB) repair factor XRCC1 17, 18 . The fact that Parp1 -/-mice, in contrast to Xrcc1 mutants, are viable and fertile suggests these mice are not completely deficient in the repair of SSBs 19, 20 . In the absence of efficient SSB repair, endogenously created lesions may persist through to S-phase, where they are converted to DSBs 21 . DSB repair is normally intact in PARP-1 -/-cells 22 but not in BRCA1/2 deficient cells 5, 23 . As such, inhibition of PARP-1 may confer selective cytotoxicity to tumor cells with attenuated BRCA function, while not impacting on the BRCA-proficient cells of the patient. In support of this, two groups demonstrated selective cytotoxicity of PARP inhibitors against cells with dysfunctional BRCA1/2 24, 25 .
In vitro analysis of PARP inhibitors in CA-PAN-1 tumor cells, derived from a liver metastasis of a human BRCA2 defective pancreas carcinoma 26 and thus far the only tumor cell line available with abrogated BRCA2 function, yielded conflicting results 27, 28 . These experiments in pancreatic tumor cells call for evaluation of PARP inhibitor efficacy in additional BRCA2-deficient tumor cells, specifically of mammary epithelial origin. The latter is important considering the cell type-intrinsic differences between mammary epithelial cells and other cells, which have been postulated to -at least partially -explain the tumor spectrum in BRCA-carriers 29 . Unfortunately, no BRCA2-deficient mammary tumor cell lines have been published until now.
Here, we report the successful establishment of clonal cell lines from two independent BRCA2-deficient mouse mammary tumors. Thorough characterization of these cell lines confirmed complete loss of BRCA2 function and increased sensitivity towards DNA damaging agents was shown for BRCA2-deficient cells as compared to BRCA2-proficient control cells. Using a novel, specific and potent inhibitor of PARP enzymatic activity, AZD2281 (Menear KA et al., manuscript submitted), we show growth inhibition of BRCA2-deficient mammary tumor cells. Since both PARP inhibition and cisplatin confer selective toxicity to BRCA2-deficient mammary tumor cells, and since PARP inhibition was recently shown to potentiate cisplatin-mediated cytotoxicity 30 , we also performed drug combination studies. AZD2281 synergized with cisplatin in inhibiting the growth of BRCA2-deficient mammary tumor cells, while this combination was additive in the BRCA2-proficient tumor cells. These data warrant further preclinical evaluation of AZD2281 as monotherapy or in combination with cisplatin in animal models for BRCA-deficient breast cancer.
Materials and methods

Establishment and maintenance of tumor cell lines
Tumor bearing female mice of the K14-Cre;Brca2 ;p53 F2-10/F2-10 (KP) genotype 31 were sacrificed and the tumors were isolated. Small (3x3 mm) pieces were subsequently minced and digested for 1 hour in Leibovitz L15 medium with 3g/l Collagenase A and 1.5g/l porcine pancreatic trypsine with rigorous shaking at 37°C. Aggregates were plated out and cultured under low oxygen conditions (3% O 2 , 5% CO 2 , 37°C) using DMEM-F12 medium (Gibco, Carlsbad, CA) supplemented with 10% fetal calf serum, 50U/ml penicillin, 50µg/ml streptomycin (Gibco, Carlsbad, CA), 5 µg/ml insulin (Sigma, St. Louis, MO), 5ng/ml EGF (Gibco, Carlsbad, CA) and 5ng/ml cholera toxin (Gentaur, Brussels, Belgium). To remove contaminating fibroblasts, cultures were differentially trypsinized until homogeneous cell morphology indicated pure epithelial cultures.
Detection of Brca2 expression by qPCR
Total RNA (1.25µg) isolated from cell cultures using a Qiagen RNeasy kit, was used as input for a first strand reaction (Invitrogen, Carlsbad, CA, according to manufacturer's protocol). Subsequently, 12ng cDNA was used for a qPCR reaction using the SYBR-Green PCR Mastermix (Applied biosystems, Foster City, CA), performed on an ABI Prism 7000. HPRT Levels were used as internal control. Brca2 primer sequences were as follows: Exon2-3 FW: gaaatttttaaggcgagatgcag; Exon2-3 RV: ccaattgaggcttatcggtcc; Exon10-11 FW: gaagcaagtgcttttgaag; Exon10-11 RV: cagaagaatctggtatacctg; Exon18-19 FW: ctcctgatgcctgtgcacc; Exon18-19 RV: cacgaaagaaccccagcct.
Detection of p53 protein
Protein extraction of cultured cells was performed using ELB buffer (150mM NaCl, 50mM Hepes pH 7.5, 5mM EDTA, 0.1% NP-40) complemented with a protease inhibitor cocktail (Roche, Basel, Switzerland). Primary antibodies used in subsequent Western blot assays: polyclonal sheep anti p53 (1:5000, Calbiochem, San Diego, CA); polyclonal goat anti β-Actin (1:2000, Santa Cruz Biotechnology, Santa Cruz, CA). Secondary antibody: Rabbit-anti-Goat HRP (1:2000, Dakocytomation, Glostrub, Danmark).
γH2A.X/RAD51 Colocalization
Cells grown on cover slips were exposed to 20Gy γ-irradiation and fixed eight hours later using 1% paraformaldehyde in PBS. Cells were permeabilized 5' in 0.1% Triton and preincubated for 1 hour at RT in staining buffer (PBS/0.5% BSA/0.15% Glycine), which was used as solvent in all subsequent steps. Incubation with primary polyclonal rabbit-anti-RAD51 antibody (a generous gift by Roland Kanaar, Erasmus medical center, Rotterdam, the Netherlands) followed for 2 hours. Secondary goat-anti-rabbit Alexa 568 (Molecular Probes, Carlsbad, CA, 1:400 dilution) was then co-incubated with FITC-conjugated monoclonal mouse-anti-γH2A.X antibody (Upstate, Billerica, MA, clone JBW301, 1:50 dilution) for 1 hour at RT. Finally, DNA was stained using 1:5000 To-Pro-3 (Molecular Probes, Carlsbad, CA). All incubations were followed by at least three wash steps using staining buffer. Slides were mounted using Vectashield (Vector Laboratories, Burlingame, CA). Images were acquired on a Leica TCS TNT system (Leica Microsystems, Wetzlar, Germany).
Array CGH
Genomic DNA isolated from primary tumors or cell lines was labeled and hybridized to 3K mouse BAC microarrays using spleen DNA originating from the same animal as a reference, as described 32 .
Karyotyping
Metaphases were prepared by culturing sub-confluent cells for 30 min. in the presence of 100ng/ml colcemid (Gibco, Carlsbad, CA). Cells were harvested and hypotonic swelling was induced for 10 min. in 0.075M KCl. Subsequently, cells were fixed using three short incubations in 3:1 dry methanol:glacial acetic acid solution and dropped on a microscope slide. Ploidy analysis was performed by mounting metaphase slides in DAPI containing Vectashield (Vector laboratories, Burlingame, CA) and images were acquired using a Zeiss Axiovert 200M fluorescence microscope, mounted with a Zeiss Axiocam MRm Rev. 2 camera. Spectral karyotyping (SKY) analysis was performed as described 33 , using the spectracube 300. Between 6 and 9 metaphases were analyzed for each cell line using Skyview software version 2.1.1. 
Sulforhodamine B (SRB) growth inhibition assays
Cells were typically plated out in 96-well microplates on day 0 and either irradiated or supplied with twofold serial drug dilutions on day 1. All drugs were left on the cells for the duration of the experiment, except for MMS, which was removed from the cells after 1 hour incubation in serum-free medium. On day 5, the cells were fixed by adding trichloroacetic acid to a final concentration of 5% (v/v). After 1 hour at 4°C, plates were washed 5 times with demi water, dried and stained for 30 min. with 50µl sulforhodamine B, 0.4% (w/v). Following three wash steps with 1% acetic acid, 150µl 10mM Tris was added to dissolve the staining. Absorbance at 540nm was measured using a Tecan infinite m200 plate reader (Tecan, Salzburg, Austria). After correction for medium-only and no-drug controls, datapoints were fitted using the general formula for a sigmoid curve using the sig-( ) 
Results
Establishment of BRCA2-deficient mammary tumor cell lines
In vitro studies on BRCA2-associated breast cancer have been hampered by the lack of appropriate BRCA2-deficient mammary tumor cell lines 24, 25 . We therefore set out to establish BRCA2-deficient mammary tumor cell lines by taking into culture 12 tumors from K14Cre;Brca2 F11/F11 ;p53 F2-10/F2-10 (KB2P) mice that develop BRCA2-deficient mammary cancer 31 . As controls for functional assays, we also established cell lines from 3 BRCA2-proficient mammary tumors harvested from K14Cre;p53 F2-10/F2-10 (KP) mice 34 . Histopathological examination of the parental tumors confirmed their resemblance to invasive ductal carcinomas (IDCs), the main tumor type in human BRCA2-mutation carriers (Supplementary Figure 1) . Low oxygen (3%) culturing conditions were continuously applied to minimize oxidative DNA damage and thereby prevent specific depletion of BRCA2-deficient cells in KB2P cultures 35 . When cultures showed homogeneous epithelial characteristics upon visual inspection, the KB2P lines were probed for Cre-mediated recombination of the Brca2 F11 alleles using Southern analysis (Figure 1A) . Whereas all corresponding primary tumors showed homozygous switching of both Brca2 F11 alleles (with a residual Brca2 Figure 1C ). Interestingly, however, absolute levels of the truncated Brca2 Δ11 transcript, which is produced after recombination, appeared to be higher in the KB2P lines, suggesting increased transcription of the Brca2 gene upon loss of functional BRCA2 ( Figure 1C ). Western blot analysis showed p53 to be absent in all established clonal cell lines, confirming Cre-mediated recombination of both p53 F2-10 alleles (Figure 1D) . Epithelial identity of all clonal cell lines was confirmed using Cytokeratin 8 and E-Cadherin staining of cultured cells (Supplementary Figure 2) .
BRCA2-deficient cell lines do not form IR induced RAD51 foci
Cre-mediated recombination within the Brca2 F11 allele results in loss of exon 11, which encodes the BRC repeats necessary for proper regulation of RAD51 protein filament formation during DSB repair by HR 7, 36 . In BRCA2-proficient cells, induction of DSBs by ionizing radiation results in rapid re-localization of both RAD51 and γH2A.X to sites of DNA damage 37 . In contrast, re-localization of RAD51 does not occur in irradiated CAPAN-1 cells with dysfunctional BRCA2 38 . To ascertain that Brca2
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∆2-10/∆2-10 KB2P cells were incapable of carrying out HR-mediated DSB repair, we assessed radiation-induced colocalization of RAD51 with γH2A.X in nuclear foci. BRCA2-proficient cells, subjected to 20Gy of γ-irradiation and harvested 8 hours later, showed profound co-localization of RAD51 and γH2A.X. In contrast, complete absence of IR-induced RAD51 foci was seen in the KB2P cells lacking wildtype BRCA2 (Figure 2 ).
BRCA2-deficient mammary tumor cell lines display genomic instability
Absence of proper DSB repair 8 , centrosome regulation 9 and cytokinesis 39 upon loss of BRCA2 is thought to result in a mutator phenotype driving additional oncogenic events. Indeed, BRCA2-deficient tumors have been shown to contain high amounts of genetic aberrations 40 . To investigate the extent of genomic gains and losses, we performed genome-wide array CGH analysis of both the parental BRCA2 tumors and the clonal cell lines derived thereof ( Figure  3A ). Many genomic regions were found to be significantly amplified (red) or deleted (green) as compared to control DNA harvested from the spleen of the tumor-bearing animal. In general, the BRCA2-deficient tumors showed much more aberrations than the BRCA2-proficient control tumors, similar to the situation in BRCA1-deficient tumors 34 . Unsupervised hierarchical clustering of all parental tumors and KB2P cell lines showed co-clustering of the KB2P-1 clones together with their ancestral tumor 1, but not of KB2P-3 clones with tumor 3 ( Figure  3A ). For subsequent ploidy analysis, metaphase spreads were prepared and stained with DAPI to count at least 18 spreads. All but one cell line (KP-6.3) were shown to be aneuploid, a general hallmark of solid tumors 41 ( Figure 3B ). To determine the contribution of individual chromosomes to the increased ploidy as well as the amount of chromosome rearrangements, we performed spectral karyotyping (SKY) analysis. BRCA2-deficient KB2P cells showed large amounts of complex translocations and in addition displayed many other structural aberrations such as deletions and the presence of satellite and marker chromosomes ( Figure 3C, D) . Besides the expected increase in structural chromosomal aberrations in the KB2P cells vs. the KP cells, we observed more clonal variation within the BRCA2 negative cells than in the controls ( Figure 3C ). The complete composite karyotype of several cells analyzed is shown in Supplementary Table 1 .
Selective sensitivity of BRCA2-deficient mammary tumor cell lines to DNA damaging drugs
Absence of proper repair of damaged DNA leads to hypersensitivity to agents affecting DNA structure. Indeed, the specific hypersensitivity of BRCA2-deficient tumor cells to DNA damaging drugs is the basis for several clinical trials in BRCA2 mutation carriers with breast or ovarian cancer 14, 15 . To evaluate the utility of our mammary tumor cell lines to model BRCA2-deficient breast cancer, sensitivity to both γ-irradiation and cisplatin was determined in growth inhibition assays. Both treatments clearly re- sulted in strong specific growth inhibition in the BRCA2 mutant KB2P lines as compared to the KP controls (Figure 4) .
The PARP inhibitor AZD2281 strongly inhibits BRCA2 -deficient cell growth
Recent experiments support the idea that inhibiting PARP-1 activity, and thus SSB repair, may induce DSBs that are specifically toxic to cells with defective HR repair, such as BRCA2-deficient cells 24, 25 . To test the utility of PARP inhibitors for treating BRCA2-associated breast cancer, we investigated selective growth inhibition of a novel PARP inhibitor, AZD2281, in our panel of BRCA2-proficient and BRCA2-deficient cell lines ( Figure 4 , Table 1 ). To compare the activity of AZD2281 with various classes of cytotoxic agents, we tested a set of 10 drugs, including compounds directly inducing DNA-strand lesions that result in DSBs Table 1 ). BRCA2 deficiency did not, on the other hand, significantly potentiate the action of the antimetabolites, the spindle poisons, doxorubicin and valproic acid. Importantly, the largest difference in drug sensitivity between BRCA2-deficient KB2P cells and BRCA2-proficient KP cells was observed for the PARP inhibitor AZD2281. Data from at least 3 independent experiments showed an average IC50 of 91nM for the KB2P lines compared to 8135nM for the KP lines, which is a highly significant (p=2.7·10 -6 ) difference of ~90 times. 
PARP inhibition synergizes with cisplatin in growth inhibition of BRCA2-deficient mammary tumor cells
Since both platinum drugs and the PARP inhibitor AZD2281 give rise to DSBs, combination therapy with platinum and AZD2281 may lead to a reduced effective dose of both single agents. This can be favorable with regard to toxic side-effects of platinum drugs. To study possible drug synergy or additivity, growth inhibition induced by combinations of 16 different concentrations of AZD2281 and 9 different concentrations of cisplatin was determined for both KB2P cell lines and a KP control cell line ( Figure 5A ). Subsequently, using the growth inhibition curves of both single agents, combination index values as explained in 42 were calculated using the formula Whereas most cisplatin and AZD2281 combinations only exerted additive growth inhibitory effects on the KP-6.3 cell line, synergistic growth inhibition was observed for both BRCA2-deficient cell lines ( Figure 5B ).
Discussion
Tumor derived cell lines are likely to recapitulate several cell-intrinsic properties of tumor cells in vivo 43 and have been used extensively as models for human cancer. For studying human hereditary breast cancer associated with BRCA2 loss-of-function, researchers have thus far relied upon the CAPAN-1 line, which carries a 6174delT mutation in one BRCA2 allele accompanied by loss of the wild-type allele 44 . This cell line originates from a pancreatic tumor and may therefore be less qualified as a model system for human BRCA2-mutated breast cancer. Growth arrest, probably caused by rapid accumulation of unrepaired DNAdamage, makes it very difficult to culture cells with dysfunctional BRCA2 4 . Consequently, no established BRCA2-deficient mammary tumor cell lines have been reported until now. Since supraphysiological oxygen levels can increase DNA damage 35 , we reasoned that cells with dysfunctional BRCA2 should be cultured at low oxygen conditions, comparable to the levels present in situ. Although this strategy resulted in the successful establishment of BRCA2-deficient cell lines from two independent primary mammary tumors, cultures derived from 10 additional tumors displayed depletion of BRCA2-deficient cells, suggesting strong selection against BRCA2 dysfunction during in vitro culture. The fact that all mammary tumors and tumor cell lines derived from K14Cre;Brca2 F11 results in a non-functional allele. In line with this, both BRCA2-deficient KB2P cell lines showed increased genomic instability, characterized by large numbers of clonal structural aberrations, compared to BRCA2-proficient KP cell lines. The high degree of genomic instability of the BRCA2-deficient KB2P cell lines is also reflected by the fact that many aberrations were not clonal, giving rise to de novo genetic heterogeneity within the clonal KB2P cell lines. This continuing genetic heterogeneity may, in combination with strong selective pressure for adaptation to in vitro growth conditions, also be the cause of the discordance between the CGH profiles of KB2P-3 clonal cell lines and the corresponding primary tumor. Interestingly, whereas tri-and quadriradial chromosome structures have been described to be a direct effect of BRCA2 dysfunction 4 , these structures were not observed in any of the metaphase spreads prepared from our KB2P cell lines (data not shown).
Although it is known that DNA damaging agents show selective cytotoxicity against non-tumor cells with engineered Brca2 mutations, relatively few data are available about the effect of such agents on BRCA2-deficient mammary tumor cells. These tumor cells are either intrinsically less sensitive to the proliferative impediment that is induced by BRCA2 loss-offunction in non-tumor cells, or have somehow overcome this inhibition, perhaps by acquiring additional mutations. For this reason it is important to assess the efficacy of known cytotoxic agents in the context of steadily proliferating BRCA2-deficient cells. We have assessed, for the first time, the selective toxicity of γ-irradiation and 11 anticancer drugs on proliferating BRCA2-deficient breast cancer cells. Our in vitro cytotoxicity studies with BRCA2-proficient KP cell lines vs. BRCA2-deficient KB2P lines clearly showed selective sensitivity of KB2P cells to cytotoxic agents directly inducing DNA strand lesions (IR, Cisplatin, MMC, MMS, Temozolomide) but not to agents that do not, or only indirectly, induce DNA damage (doxorubicin, 5FU, HU, docetaxel, nocodazol, valproic acid). Temozolomide displayed an exquisite 46-fold higher sensitivity towards BRCA2-deficient cells. This strong selectivity may be explained by the fact that temozolomide indirectly induces DSBs as a result of futile mismatch repair of O6-methylguanine lesions 45 . Our results highlight, for the first time, the potential efficacy of temozolomide against BRCAmutated breast cancer, and warrant further investigation. Still, the strongest selective sensitivity of KB2P cells was observed with the clinical PARP inhibitor AZD2281. One explanation for the unrivaled sensitivity of BRCA2-defective cells towards AZD2281 is that suppression of BER by PARP inhibition may result in the conversion of SSBs to DSBs during DNA replication, thus activating BRCA2 dependent recombination pathways 21 . The two independently isolated BRCA2-deficient cell lines show very similar responses to all agents tested, as do the three independent BRCA2-proficient lines. Nevertheless, definitive proof of BRCA2 directly being responsible for the differential effects between these groups of cell lines should come from reconstitution experiments that should rule out that other mutations are causal to the observed sensitization spectrum.
The initial reports on the selective sensitivity of BRCA2-deficient cells to PARP inhibition were challenged by other studies, which claimed that known PARP inhibitors were not or only minimally selective to BRCA2 mutant CAPAN-1 tumor cells and BRCA1 mutant tumor cells 27, 46 . Although CAPAN-1 cells were subsequently shown to be highly sensitive to the PARP inhibitor used in one of the original studies 28 , these experiments did not rule out the possibility that cell type related differences might compromise the utility of PARP inhibitors for treating BRCA-associated breast cancer. This concern is alleviated by the potent growth inhibition induced by the clinical PARP inhibitor AZD2281 in our BRCA2-deficient mammary cancer cell lines. Whether the strong growth inhibition induced by AZD2281 also applies to BRCA1-deficient tumor cells remains yet to be determined.
Most known PARP inhibitors inhibit PARP-1 as well as PARP-2 activity 24 and, in contrast to PARP-1 single knockouts, PARP-1/ PARP-2 double knockout mice are embryonic lethal 47 . Indeed, PARP-1 and PARP-2 have both overlapping and non-redundant functions in the maintenance of genomic stability 48 . Nevertheless, both the large differential effect between BRCA2-deficient and -proficient cells and the absence of apparent toxic effects in mice treated with AZD2281 (data not shown) indicate that partial inhibition of PARP-1 and PARP-2 by AZD2281 does not cause notable toxicity in wild type cells.
In summary, we have generated the first set of BRCA2-deficient mammary tumor cell lines, which may prove useful for mechanistic studies and for preclinical evaluation of novel anti-cancer drugs. In vitro cytotoxicity studies with these cell lines showed clear selective sensitivity of BRCA2-deficient cells to drugs that induce DNA strand lesions or compounds that target the BER pathway. Moreover, potent synergy between the clinical PARP inhibitor AZD2281 and cisplatin was observed. Taken together, our results provide strong evidence for the use of selective PARP inhibitors alone, or in combination with platinum drugs for the treatment of BRCA-associated cancers and BRCA-like tumors with defective HR repair. Cells seeded on coverslips and harvested 24 hours later were stained for cytokeratin 8 (green, A) or E-cadherin (green, B), and DNA (blue) as described 1 . Subsequently, pictures were taken using a Leica TCS TNT microscope (Leica Microsystems, Wetzlar, Germany). 
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